留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

结缔组织病相关间质性肺疾病:必须重视的疾病

陈志磊 张奉春

陈志磊, 张奉春. 结缔组织病相关间质性肺疾病:必须重视的疾病[J]. 协和医学杂志, 2018, 9(3): 193-196. doi: 10.3969/j.issn.1674-9081.2018.03.001
引用本文: 陈志磊, 张奉春. 结缔组织病相关间质性肺疾病:必须重视的疾病[J]. 协和医学杂志, 2018, 9(3): 193-196. doi: 10.3969/j.issn.1674-9081.2018.03.001
Zhi-lei CHEN, Feng-chun ZHANG. Connective Tissue Disease-Associated Interstitial Lung Disease: a Disease Worthy of Great Attention[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 193-196. doi: 10.3969/j.issn.1674-9081.2018.03.001
Citation: Zhi-lei CHEN, Feng-chun ZHANG. Connective Tissue Disease-Associated Interstitial Lung Disease: a Disease Worthy of Great Attention[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 193-196. doi: 10.3969/j.issn.1674-9081.2018.03.001

结缔组织病相关间质性肺疾病:必须重视的疾病

doi: 10.3969/j.issn.1674-9081.2018.03.001
详细信息
    通讯作者:

    张奉春 电话:010-69155007, E-mail:zhangfccra@aliyun.com

  • 中图分类号: R563.1+3;R593.2

Connective Tissue Disease-Associated Interstitial Lung Disease: a Disease Worthy of Great Attention

More Information
  • 摘要: 结缔组织病(connective tissue disease, CTD)是以自身免疫及其介导的器官系统损伤为特征的一组全身性疾病。肺部并发症是CTD的重要关节外表现, 也是CTD患者死亡的主要原因。临床管理CTD相关间质性肺疾病(CTD-associated interstitial lung disease, CTD-ILD)的关键是确定ILD类型、疾病所处阶段、应给予何种治疗。目前CTD-ILD仍采用特发性间质性肺炎分类, 其诊断治疗尚无统一的临床指导策略。越来越多的研究发现, 自身抗体与CTD-ILD相关, 对临床诊治具有一定指导意义, 临床实践中应更多关注那些肺部表现不明显的CTD患者, 以尽早识别CTD-ILD, 给予适当治疗, 延缓疾病进展。
  • [1] Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement:update on the international multidisciplinary classification of the idiopathic interstitial pneumonias[J]. Am J Respir Crit Care Med, 2013, 188:733-748. doi:  10.1164/rccm.201308-1483ST
    [2] Wells AU, Denton CP. Interstitial lung disease in connective tissue disease-mechanisms and management[J]. Nat Rev Rheumatol, 2014, 10:728-739. doi:  10.1038/nrrheum.2014.149
    [3] 张奉春.弥漫性结缔组织病的肺间质病变[J].中华临床免疫和变态反应杂志, 2008, 2:171-172. doi:  10.3969/j.issn.1673-8705.2008.03.001
    [4] Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome[J]. Am J Respir Crit Care Med, 2002, 165:1581-1586. doi:  10.1164/rccm.2106012
    [5] Ueda T, Sakagami T, Kikuchi T, et al. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis[J]. Respir Investig, 2018, 56:14-20. doi:  10.1016/j.resinv.2017.11.004
    [6] Karampitsakos T, Tzouvelekis A, Chrysikos S, et al. Pulmonary hypertension in patients with interstitial lung disease[J]. Pulm Pharmacol Ther, 2018, pii: S1094-5539(17)30242-0. http://www.sciencedirect.com/science/article/pii/S1094553917302420
    [7] Koduri G, Norton S, Young A, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis results from an inception cohort[J]. Rheumatology (Oxford), 2010, 49:1483-1489. doi:  10.1093/rheumatology/keq035
    [8] Tsuchiya Y, Takayanagi N, Sugiura H, et al. Lung diseases directly associated with rheumatoid arthritis and their relation to outcome[J]. Eur Respir J, 2011, 37:1411-1417. doi:  10.1183/09031936.00019210
    [9] Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis[J]. Ann Rheum Dis, 2004, 63:297-301. doi:  10.1136/ard.2003.006122
    [10] Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyo-sitis-dermatomyositis-associated interstitial lung disease[J]. Am J Respir Crit Care Med, 2001, 164:1182-1185. doi:  10.1164/ajrccm.164.7.2103110
    [11] Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjögren syndrome[J]. Chest, 2006, 130:1489-1495. doi:  10.1378/chest.130.5.1489
    [12] Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjögren's syndrome:a clinical, radiologic, and pathologic study[J]. Am J Respir Crit Care Med, 2005, 171:632-638. doi:  10.1164/rccm.200403-417OC
    [13] Bertoli AM, Vila LM, Apte M, et al. Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVⅢ:factors predictive of pulmonary damage[J]. Lupus, 2007, 16:410-417. doi:  10.1177/0961203307079042
    [14] Swigris JJ, Fischer A, Gillis J, et al. Pulmonary and thrombotic manifestations of systemic lupus erythematosus[J]. Chest, 2008, 133:271-280. doi:  10.1378/chest.07-0079
    [15] Lee JS, Fischer A. Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease[J]. Expert Rev Clin Immunol, 2016, 12:509-520. doi:  10.1586/1744666X.2016.1139454
    [16] Denton CP, Hughes M, Gak N, et al. BSR and BHPR guideline for the treatment of systemic sclerosis[J]. Rheumatology, 2016, 55:1906-1910. doi:  10.1093/rheumatology/kew224
    [17] Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis[J]. Lung, 2009, 187:201-206. doi:  10.1007/s00408-009-9146-6
    [18] Ball EM, Savage EM, Pendleton A. Refractory anti-synthetase syndrome treated with rituximab[J]. Rheumatology (Oxford), 2010, 49:1013. doi:  10.1093/rheumatology/kep438
    [19] Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders[J]. Lancet, 2012, 380:689-698. doi:  10.1016/S0140-6736(12)61079-4
    [20] Bonella F, Costabel U. Biomarkers in connective tissue disease associated interstitial lung disease[J]. Semin Respir Crit Care Med, 2014, 35:181-200. doi:  10.1055/s-0034-1371527
    [21] 张亚妹, 彭清林, 卢昕, 等.抗PUF60抗体在中国特发性炎性肌病患者中的分布及临床意义[J].协和医学杂志, 2017, 4:244-250. doi:  10.3969/j.issn.1674-9081.2017.05.010
  • 加载中
计量
  • 文章访问数:  177
  • HTML全文浏览量:  12
  • PDF下载量:  277
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-05-03
  • 刊出日期:  2018-05-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!